薄芝糖肽注射液治疗大面积寻常型银屑病的临床疗效及安全性评价

The Research on Clinical Curative Effect and Safety of Bozhi Glycopeptide Injection in the Treatment of Large Areas of Psoriasis Vulgaris

目的:评价薄芝糖肽注射液治疗大面积寻常型银屑病的临床疗效及安全性。方法:106例大面积寻常型银屑病患者随机分为对照组及试验组,各53例.对照组给予阿维A胶囊30mg,qd,口服,试验组在对照组基础上加用薄芝糖肽注射液4mL,qd,静脉滴注。比较两组患者治疗前后血清肿瘤坏死因子α(TNF-α)、白细胞介素6(IL-6)、白细胞介素17A(IL-17A)、白细胞介素-22(IL-22)、干扰素γ(INF-γ)、血管内皮生长因子(VEGF)、可溶性E选择素(s E-slelctin)、可溶性细胞间黏附分子-1(sICAM-1)水平、治疗有效率及不良反应发生率。结果:治疗后,对照组患者血清TNF-α、IL-6、IL-17A、IL-22、INF-γ、VEGF、s E-slelctin、sICAM-1水平分别为(91.65±12.87)pg/mL、(89.76±11.08)pg/mL、(16.46±1.55)pg/mL、(45.23±6.11)pg/mL、(16.52±2.47)pg/mL、(152.34±20.08)pg/mL、(43.29±5.78)ng/mL、(117.21±10.29)μg/L,试验组患者上述指标水平分别为(49.57±7.02)pg/mL、(58.46±7.66)pg/mL、(10.75±1.23)pg/mL、(38.23±5.01)pg/mL、(9.75±1.32)pg/mL、(123.12±12.54)pg/mL、(29.55±4.21)ng/mL、(98.75±12.13)μg/L,与对照组比较,试验组患者血清TNF-α、IL-6、IL-17A、IL-22、INF-γ、VEGF、s E-slelctin、sICAM-1水平较低(P<0.05)。试验组的治疗有效率(90.58%)高于对照组(67.92%)(P<0.05)。两组患者不良反应发生率差异无统计学意义(P>0.05)。结论:薄芝糖肽注射液能够明显降低大面积寻常型银屑病患者血清TNF-α、IL-6、IL-17A、IL-22、INF-γ、VEGF、sE-slelctin及sICAM-1水平,减轻炎症反应,抑制血管新生,具有较高的临床疗效及安全性。

Objective: To evaluate the clinical curative effect and safety of Bozhi Glycopeptide Injection in the treatment of large areas of psoriasis vulgaris. Methods: One hundred and six cases of patients with large areas of psoriasis vulgaris were randomly divided into the control group and treatment group,53 cases in each group. The control group was given A citretin capsule 30 mg,qd,orally,on the basis of the control group,the experimental group was treated with Shen Qi Bozhi Glycopeptide Injection 4 ml,qd,intravenous drip. Before and after treatment,compared between the two groups of patients with serum tumor necrosis factorα( TNF-α),interleukin 6( IL-6),interleukin 17 A( IL-17 A) levels,interleukin-22( IL-22),interferonγ( INF-γ),vascular endothelial growth factor( VEGF),soluble E selectin( s E-slelctin),soluble intercellular adhesion molecule-1( sICAM-1),efficiency of treatment and incidence of adverse reactions. Results: After treatment,serum levels of TNF-α,IL-6,IL-17 A,IL-22,INF-γ,VEGF,s E-slelctin,sICAM-1 in the control group respectively were( 91.65±12.87) pg/mL,( 89.76±11.08) pg/mL,( 16.46±1.55) pg/mL,( 45.23±6.11) pg/mL,( 16.52 ± 2.47) pg/mL,( 152.34 ± 20.08) pg/mL,( 43.29 ± 5.78) ng/mL,( 117.21 ± 10.29) μg/L,,the levels of the above indicators in the experimental group respectively were( 49.57±7.02) pg/mL,( 58.46±7.66) pg/mL,( 10.75 ± 1. 23) pg/mL,( 38. 23 ± 5. 01) pg/mL,( 9. 75 ± 1. 32) pg/mL,( 123. 12 ± 12. 54) pg/mL,( 29.55±4.21) ng/mL,( 98.75±12.13) μg/L,compared with the control group,the serum levels of TNF-α,IL-6,IL-17 A,IL-22,INF-γ,VEGF,s E-slelctin,sICAM-1 were lower in the experimental group( P<0.05). The treatment efficiency of the experimental group( 90.58%) was significantly higher than that of the control group( 67.92%)( P <0.05). There was no significant difference in the incidence of adverse reactions between the 2 groups( P > 0.05). Conclusion: The Bozhi Glycopeptide Injection can significantly reduce the serum levels of TNF-α,IL-6,IL-17 A,IL-22,INF-γ,VEGF,s E-slelctin and sICAM-1 in patients with large areas of psoriasis vulgaris,inhibit angiogenesis,improve clinical efficacy,and have high clinical efficacy and safety.